← Back to Search

Observation for Multiple Sclerosis (MS-GDI Trial)

N/A
Recruiting
Led By Milap Sandhu, PhD
Research Sponsored by Shirley Ryan AbilityLab
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at the time of session
Awards & highlights
No Placebo-Only Group

Summary

The purpose of this study is to develop a measurement of walking quality, called Gait Deviation Index (GDI) for people with Multiple Sclerosis (MS).

Eligible Conditions
  • Multiple Sclerosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at the time of session
This trial's timeline: 3 weeks for screening, Varies for treatment, and at the time of session for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Kinematics of the gait cycle
Secondary study objectives
6 minute walk test

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: ObservationExperimental Treatment1 Intervention
Gait quality observation

Find a Location

Who is running the clinical trial?

Shirley Ryan AbilityLabLead Sponsor
208 Previous Clinical Trials
17,985 Total Patients Enrolled
7 Trials studying Multiple Sclerosis
385 Patients Enrolled for Multiple Sclerosis
Milap Sandhu, PhDPrincipal InvestigatorShirley Ryan AbilityLab
2 Previous Clinical Trials
116 Total Patients Enrolled
~23 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top